{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:49Z","timestamp":1791410809477,"version":"4.3.3"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 66-year-old man with a history of non\u2013small cell lung cancer treated with nivolumab underwent contrast-enhanced CT and FDG PET\/CT. No recurrence was demonstrated; however, soft-tissue thickening that showed delayed contrast enhancement and FDG uptake was detected around an abdominal aortic aneurysm. After discontinuation of nivolumab, the periaortic lesion disappeared within 2 months, indicating nivolumab-induced periaortitis. Immune checkpoint inhibitors such as nivolumab can cause vasculitis and periaortitis, a potentially fatal condition, as immune-related adverse events. The underlying aortic aneurysm may have contributed to genesis of periaortitis. FDG PET\/CT can be useful for detecting periaortitis and excluding other forms of vasculitis.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003215","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T21:25:14Z","timestamp":1601501114000},"page":"910-912","source":"Crossref","is-referenced-by-count":16,"title":["Nivolumab-Induced Periaortitis Demonstrated by FDG PET\/CT"],"prefix":"10.1097","volume":"45","author":[{"given":"Masatoshi","family":"Hotta","sequence":"first","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Naka","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryogo","family":"Minamimoto","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takeda","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hojo","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non\u2013small-cell lung cancer: results from the CA209-003 study","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","year":"2020","journal-title":"JAMA Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-019-0828-7","article-title":"Systemic vasculitis associated with immune check point inhibition: analysis and review","volume":"21","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"H1052","DOI":"10.1152\/ajpheart.00024.2017","article-title":"Immune checkpoint dysfunction in large and medium vessel vasculitis","volume":"312","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","year":"2018","journal-title":"Clin Rheumatol"},{"key":"bib7-20230925","article-title":"Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy","year":"2017","journal-title":"BMJ Case Rep"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.molmed.2008.09.008","article-title":"Abdominal aortic aneurysms: an autoimmune disease?","volume":"14","year":"2008","journal-title":"Trends Mol Med"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1148\/rg.2018180049","article-title":"IgG4-related cardiovascular disease from the aorta to the coronary arteries: multidetector CT and PET\/CT","volume":"38","year":"2018","journal-title":"Radiographics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:17:11Z","timestamp":1695622631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003215","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}